drugset / Trial / NCT02860858

Intravitreal Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy (PCV)

NCT02860858

NaSingle-groupOpen-labelTreatment

Summary

Objective: To evaluate the efficacy of intravitreal aflibercept injection on visual acuity in patients with symptomatic macular PCV.

Timeline

Start
2016-12-30
Primary completion
2018-08-30
Completion
2018-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Aflibercept Protein / enzyme biologic Intravitreal

Indications

No indication recorded.